Preparing for preventive clinical trials: The predict-HD study

Archives of Neurology

Volumn 63, Issue 6, 2006, Pages 883-890

  Paulsen, Jane S ^a   Hayden, Michael ^c   Stout, Julie C ^d   Langbehn, Douglas R ^a,b   Aylward, Elizabeth ^e   Ross, Christopher A ^f   Guttman, Mark ^g   Nance, Martha ^h   Kieburtz, Karl ^i,j   Oakes, David ^j   Shoulson, Ira ^i,j   Kayson, Elise ⁱ   Johnson, Shannon ^d   Penziner, Elizabeth ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d INDIANA UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^j UNIVERSITY OF ROCHESTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; BASAL GANGLION; CANADA; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DNA DETERMINATION; FEMALE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; UNITED STATES;

ADULT; AGE FACTORS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; HUNTINGTON DISEASE; INTERNATIONAL COOPERATION; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PROBABILITY; TRINUCLEOTIDE REPEATS;

EID: 33745110056     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.63.6.883     Document Type: Article

References (33)

1. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291:1304-1351.
2. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on the Huntington's disease chromosomes. Cell. 1993;72:971-983.
3. Langbehn DR, Brinkman R, Faulush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004;65:267-277.
4. Djousse L, Knowlton B, Hayden M, et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet A. 2003;119:279-282.
5. Li JL, Hayden MR, Almqvist EW, et al. A genome scan for modifiers of age at onset in Huntington disease: the HD MAPS study. Am J Hum Genet. 2003;73:682-687.
6. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11:136-142.
7. Hogarth P, Kayson E, Kieburtz K, et al. Inter-rater agreement in the assessment of the motor manifestations of Huntington's disease. Mov Disord. 2005;20:293-297.
8. Warner JP, Barron LH, Brock DJ. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol Cell Probes. 1993;7:235-239.
9. Aylward EH, Codori A, Barta P, et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington's disease. Arch Neurol. 1996;53:1293-1296.
10. Aylward EH, Li Q, Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology. 1997;48:394-399.
11. Rothlind JC, Bylsma FW, Peyser C, Folstein SE, Brandt J. Cognitive and motor correlates of everyday functioning in early Huntington's disease. J Nerv Ment Dis. 1993;181:194-199.
12. Collewijn H, Went LN, Tamminga EP, Vegter-Van der Vlis M. Oculomotor defects in patients with Huntington's disease and their offspring. J Neurol Sci. 1988;86:307-320.
13. de Boo GM, Tibben A, Lanser JB, et al. Early cognitive and motor symptoms in identified carriers of the gene for Huntington's disease. Arch Neurol. 1997;54:1353-1357.
14. Giordani B, Berent S, Boivin MJ, et al. Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease. Arch Neurol. 1995;52:59-64.
15. Tian JR, Zee DS, Lasker AG, Folstein SE. Saccades in Huntington's disease: predictive tracking and interaction between release of fixation and initiation of saccades. Neurology. 1991;41:875-881.
16. Penney JB Jr, Young AB, Shoulson I, et al. Huntington's disease in Venezuela: 7 years of follow-up of at risk and symptomatic individuals [abstract]. Neurology. 1988;38(suppl 1):358.
17. Young AB, Shoulson I, Penney JB, et al. Huntington's disease in Venezuela: neurological features and functional decline. Neurology. 1986;36:244-249.
18. Beenen N, Buttner U, Lange HW. The diagnostic value of eye movement recordings in patients with Huntington's disease and their offspring. Electroencephalogr Clin Neurophysiol. 1986;63:119-127.
19. Siemers E, Foroud T, Bill DJ, et al. Motor changes in presymptomatic Huntington's disease gene carriers. Arch Neurol. 1996;53:487-492.
20. Aylward EH, Roberts-Twillie J, Barta P, et al. Basal ganglia volumes and white matter hyperintensities in bipolar disorder. Am J Psychiatry. 1994;151:687-693.
21. Aylward EH, Brandt J, Codori AM, et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology. 1994;44:823-828.
22. Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord. 2000;15:552-560.
23. Aylward EH, Sparks BF, Field KM, et al. The onset and rate of striatal atrophy in preclinical Huntington disease. Neurology. 2004;63:66-72.
24. Berrios GE, Wagle AC, Markova IS, et al. Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers. Psychiatry Res. 2001;102:217-225.
25. Harper PS, Lim C, Craufurd D. Ten years of presymptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium. J Med Genet. 2000;37:567-571.
26. Weissman MM, Bland RC, Canino GJ, et al. Prevalence of suicide ideation and suicide attempts in nine countries. Psychol Med. 1999;29:9-17.
27. Robins Wahlin T-B, Backman L, Lundin A, et al. High suicidal ideation in persons testing for Huntington's disease. Acta Neurol Scand. 2000;102:150-161.
28. Folstein SE. The psychopathology of Huntington's disease. In: McHugh PR, McKusick VA, eds.Genes, Brain, and Behavior. Vol 69. New York, NY: Raven Press; 1991:181-191.
29. Mendez MF. Huntington's disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med. 1994;24:189-208.
30. Hemels ME, Koren G, Einarson TR. Increased use of antidepressants in Canada: 1981-2000. Ann Pharmacother. 2002;36:1375-1379.
31. Middleton N, Gunnell D, Whitley E, Dorling D, Frankel S. Secular trends in antidepressant prescribing in the UK, 1975-1998. J Public Health Med. 2001;23:262-267.
32. Olfson M, Marcus SC, Druss B, et al. National trends in the outpatient treatment of depression. JAMA. 2002;287:203-209.
33. King M. Alcohol abuse and Huntington's disease. Psychol Med. 1985;15:815-819.